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Identity 
HGNC (Hugo): LIMD1 
Location: 3p21.31 




The gene encompasses 86432 bp and lies in the plus 
strand, starting at 45636323 and ending at 45722754 bp 
from pter, within C3CER1 (chromosome 3 common 
eliminated region 1) at  
chromosome 3p21.3, a region frequently deleted in 
solid tumours. The 5'-promoter region includes a 
negative regulatory element and a CpG island that 
contains a putative TATA box and an experimentally 
validated core basal promoter region of 21 bp (Sharp et 
al., 2008). The core promoter region contains four CpG 
methylation sites (Sharp et al., 2008). 
Transcription 
The transcript (NCBI ID: NM_014240.2) of 6284 bp 
comprises eight exons, the first of which encodes the 
N-terminal pre-LIM region. Exons 2 to 8 encode three 
LIM domains in tandem. The size of the open reading 
frame is 5129 bp. 
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The eight exons of the LIMD1 gene are denoted by open rectangles; the protein coding regions of the exons are coloured in blue. Exons 
2 to 8 encode three LIM domains in tandem. Exon 1 encodes the N-terminal pre-LIM region. Regions important for transcriptional 
regulation upstream of the start codon (ATG, +1) are denoted by black rectangles. Experimental evidence suggests that a negative 
regulatory element (-ve RE) occurs in the region between -2039 and -1539. The CpG island between -1299 and -439 contains a putative 






LIMD1 (676 amino acids, 72 kDa, NCBI ID: 
NP_055055.1) belongs to the Ajuba LIM protein 
subgroup of the Ajuba/Zyxin protein family. This six-
member family (see Homology) is characterised by a 
varied proline-rich pre-LIM region at the N-terminus 
followed by three homologous LIM domains arranged 
in tandem at the C-terminus. LIM domains (InterPro 
ID: IPR001781) coordinate two zinc ions in a tandem 
zinc-finger topology and mediate protein-protein 
interactions (Kadrmas and Beckerle, 2004). The three 
LIM domains of LIMD1 are an inherent nuclear 
localisation signal (NLS) (Sharp et al., 2004). The pr -
LIM region includes the pRB binding region and a 
nuclear export signal (NES) partially overlapping the 
N-terminal LEM-like domain (Sharp et al., 2004). 
Expression 
LIMD1 is ubiquitously expressed, but at a lower level 
in the brain and testis (Kiss et al., 1999). 
Localisation 
LIMD1 shuttles between the cytoplasm and nucleus, 
but is not found in the nucleoli (Sharp et al., 2004). In 
the cytoplasm, LIMD1 colocalises with focal adhesion  
(Huggins and Andrulis, 2008; Petit et al., 2005), 
adherens junctions (Das Thakur et al., 2010) and 





LIMD1 is involved in a range of cellular functions 
(listed below). A common theme is that LIMD1 acts as 
a protein-protein scaffold or mediator to facilitate 
signalling between cytoplasmic components and the 
nucleus. Functional redundancy between LIMD1 and 
the other Ajuba LIM proteins has also been proposed in 
a variety of cases (Das Thakur et al., 2010; Feng and 
Longmore, 2005; James et al., 2010; Langer et al., 
2008). 
- LIMD1 inhibits E2F-mediated transcription and thus 
cell proliferation via interaction with pRB and also via 
a pRB-independent mechanism that has yet to be 
clarified (Sharp et al., 2004). 
- LIMD1 stimulates stress osteoclastogenesis (Feng et 
al., 2007) and regulates osteoblast differentiation and 
function (Luderer et al., 2008). LIMD1 can act as both 
a positive regulator of osteoclast and osteoblast 
development, by linking the p62/sequestosome protein 
and TRAF6 to form a p62/TRAF6/a-PKC complex 
which can activate NF-kB and AP-1 (Feng and 
Longmore, 2005; Feng et al., 2007), and a negative 
regulator of osteoblast differentiation, by repressing 
canonical Wnt/beta-catenin signalling in osteoblasts 
(Luderer et al., 2008). 
- LIMD1 facilitates miRNA-mediated silencing by (i) 
binding to eIF4E to prevent recruitment of 4EBP1 and 
eIF4G to the mRNA 5' m(7)GTP cap, and (ii) creating 
an inhibitory closed-loop complex by acting as a 
scaffold to link eIF4E at the 5' cap to Ago1/Ago2 in the 
miRISC complex bound at the 3' UTR of mRNA 
(James et al., 2010). 
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LIMD1 can be split primarily into the N-terminal pre-LIM region (residues 1 to 471) and the C-terminal triple LIM domains (residues 472 to 
676). The pre-LIM region contains a proline/serine-rich region (residues 69 to 471), a LEM-like domain (residues 18 to 68), a nuclear 
export signal (NES, residues 54 to 134) and the binding site for pRB (residues 404 to 442). The three LIM domains are an inherent 
nuclear localisation signal (NLS, residues 472 to 676). 
 
- LIMD1 interacts with LATS/Warts and WW45/Sav to 
inhibit Hippo (Hpo) signalling pathway-mediated 
phosphorylation and nuclear-targeting of YAP/Yki 
(Das Thakur et al., 2010). Implication of the Hpo 
pathway in cell contact growth inhibition, and the 
observation that in confluent cells with no further 
proliferation, Ajuba LIM proteins gather at adherens 
junctions whilst YAP is phosphorylated and returned to 
the cytosol has led Das Thakur et al. (2010) to propose 
that Ajuba LIM proteins "release" LATS/Warts upon 
localisation at adherens junctions, leading to growth 
inhibition. 
- In the nucleus, LIMD1 interacts with the SNAG 
domain of Snail/Slug transcriptional repressors and cts 
as a co-repressor of E-cadherin and other Snail-
regulated genes to affect neural crest development and 
possibly epithelial-mesenchymal transitions (Langer et 
al., 2008). 
- Huggins and Andrulis (2008) suggested that LIMD1 
may play a part in cell anchoring as a component of 
focal adhesions and in the cell cycle (especially during 
mitosis), based on the respective observations that
LIMD1 colocalises with vinculin at focal adhesions and 
that phosphorylation of LIMD1 occurs during mitosis 
in HeLa cells. 
Homology 
The phylogenetic tree below shows the evolutionary 
distance (as inferred from amino acid sequence) 
between LIMD1 and the five other members of the 
Ajuba/Zyxin protein family (James et al., 2010). 
LIMD1 is most closely related to the other Ajuba LIM 
proteins, Ajuba and WTIP (respectively 41% and 39% 
identity overall and 64% and 72% identity in the LIM 
domains).  
In contrast, LIMD1 shares only 32%, 33% and 34% 
identity overall and 43%, 46% and 41% identity in the 
LIM domains with the Zyxin LIM proteins, Zyxin, LPP 
and TRIP6 respectively. 
The orthologue of LIMD1 in mus musculus shares 77% 
identity overall and 96% identity in the LIM domains 




Lung cancer is the primary cause of cancer-related 
deaths worldwide. Although smoking is the major 
trigger for lung cancer, another important risk factor 
involves exposure to harmful air-borne particles, such 
as asbestos or industrial pollutants. 
Cytogenetics 
Loss of coding sequence from chromosome 3p is one 
of the most common mutations found in both small cel  
(almost 100%) and non-small cell (almost 90%) lung 
cancers. The C3CER1 region (containing LIMD1) of 
chromosome 3p21.3 is more frequently deleted in solid 
malignancies than any of the other 3p regions studied 
(Petursdottir et al., 2004). Particularly in lung tumours, 
loss of heterozygosity (LOH) at C3CER1 (over 90%) 
exceeds that of tumour suppressor gene (TSG) VHL 
(72%) and putative TSG FHIT (65%) (Petursdottir et 
al., 2004). Homozygous gene deletion, LOH and 
epigenetic silencing via promoter hypermethylation - 
but not coding sequence mutations - contribute towards 
reduced expression of LIMD1 in human lung tumours 
(Sharp et al., 2008). 
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Oncogenesis 
The expression of LIMD1, a bona fide lung tumour 
suppressor, was down-regulated in all lung cancers 
analysed compared with normal tissue (Sharp et al., 
2008). From a genetic perspective, increased lung 
tumour incidence and volume was observed in the 
offspring of LIMD1 knockout (Limd1-/-) mice cross 
bred with K-RasG12D mice, an established K-Ras-
induced lung cancer model (Sharp et al., 2008). 
LIMD1, which interacts with pRB to repress E2F-
responsive transcription, reduces cell proliferation n 
vitro and incidence of lung metastases in vivo (Sharp et 
al., 2004). Loss of LIMD1 expression leading to 
misregulation of pRB and the cell cycle may therefo 
be an early critical step in lung tumour development 
(Sharp et al., 2004). 
Breast cancer 
Disease 
Breast cancer is the leading cause of cancer-related 
deaths of women in the western world. Increasing age, 
non-vegetarian diets, social class, nulliparity and 
familial history of breast cancer have been observed to 
increase the probability of breast cancer development. 
Prognosis 
LIMD1 has been proposed to be a prognostic marker 
for breast cancer, as absence of nuclear LIMD1 
staining correlates strongly to poor tumour prognosis 
and patient mortality (Spendlove et al., 2008). 
Cytogenetics 
Although alteration or deletion of chromosome 3p is 
common in breast cancers, LIMD1 was not mutated or 
deleted in most of the breast tumours analysed 
(Huggins et al., 2007) and LIMD1 mRNA levels were 
also found to be unchanged in breast cancers compared 
to normal tissues (Huggins and Andrulis, 2008). 
Oncogenesis 
Delocalisation of LIMD1 from the nucleus may 
contribute to breast cancer progression, as nuclear 
LIMD1 acts as a Snail co-repressor of E-cadherin 
expression and Snail-mediated repression of E-cadherin 
has been implicated in tumour metastasis (Langer et al., 
2008; Spendlove et al., 2008). 
Head and neck squamous cell 
carcinoma (HNSCC) 
Disease 
HNSCCs account for 90% of all head and neck cancers 
and 30-40% of cancer types in Indian patients. 
Globally, over 0,5 million new cases are diagnosed 
every year. Risk factors include smoking, alcohol, betel 
nut leaf liquid, HPV-16/18 infection and inadequate 
oral hygiene. 
Prognosis 
Ghosh et al. (2010) have suggested LIMD1 as a 
"predictive clinical marker" for HNSCC from their 
multivariate analysis showing significant correlation of 
LIMD1 alteration (deletion/methylation/mutation) to 
poor prognosis in HPV-negative patients addicted to 
tobacco. 
Cytogenetics 
Loss of heterozygosity in chromosome 3p21.3 was 
found to be highly frequent in Indian HNSCC patients 
(Ghosh et al., 2008). The same group later reported 
alteration of LIMD1 in the majority of HNSCC 
samples studied, and increasing mutation, but not 
deletion or methylation, with tumour progression 
(Ghosh et al., 2010). Six mutations in exon 1, an intron 
4/exon 5 splice-junction mutation in LIMD1 and a 
(CA)20 polymorphism of the hmlimd1 microsatellite 
marker were reported, some of which lead to non-
functional LIMD1 or reduced expression of LIMD1 
(Ghosh et al., 2010). 
Oncogenesis 
Ghosh et al. (2010) have proposed that repression of 
LIMD1, rather than pRB, is crucial for HNSCC 
development, due to the higher frequency of LIMD1 
alterations compared with pRB alterations in the 
HNSCC samples analysed and better survival of 
patients with LIMD1+/pRB- compared with LIMD1-
/pRB+. 
Paget's disease of the bone (paget's 
disease) 
Disease 
Paget's disease involves pathological bone resorption 
triggering compensatory osteoblast activity, which 
results in the formation of hypercellular, deformed 
bones. This chronic disease can be familial or sporadic. 
Prognosis 
In the regulation of osteoclast and osteoblast 
development, LIMD1 interacts with cytosolic protein 
p62, which is sometimes mutated in Paget's disease 
(Feng et al., 2007; Luderer et al., 2008). As none f the 
reported Pagetic mutations of p62 are predicted to 
affect its binding to LIMD1, and coinciding phenotypes 
were observed between LIMD1-null mice and p62-null 
mice, it was suggested that LIMD1 may act as a 
complex with mutated p62 in the development of 
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